ACP
MLTX icon

Acuta Capital Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Acuta Capital Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.57M Buy
191,760
+132,480
+223% +$2.19M 2.52% 12
2025
Q4 		$781K Buy
+59,280
New +$699K 0.53% 23
2023
Q1 		– Sell
-93,500
Closed -$982K – 39
2022
Q4 		$982K Buy
+93,500
New +$831K 0.6% 27

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acuta Capital Partners's MLTX Position: Q1 2026 in Review

Acuta Capital Partners increased its MoonLake Immunotherapeutics (MLTX) stake by 223% in Q1 2026, buying an estimated $2.19M and bringing the position to 191,760 shares worth $3.57M. The position accounts for 2.52% of the portfolio, ranked #12.

Acuta Capital Partners first reported a position in MLTX in Q4 2022 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Acuta Capital Partners held 191,760 shares of MoonLake Immunotherapeutics worth $3.57M as of Q1 2026.
  • Acuta Capital Partners bought 132,480 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $2.19M.
  • MoonLake Immunotherapeutics made up 2.52% of Acuta Capital Partners's portfolio in Q1 2026, its #12 holding.
  • Acuta Capital Partners first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.